Chronic Inflammatory Demyelinating Polyneuropathy

>

The NeurologyLive® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical focus page is a concentrated place for the latest information on the care and management of patients with CIDP. This page includes podcasts, videos and expert interviews, and news about the latest study and clinical trial findings, FDA actions, and clinical guideline updates.

Latest News

Filip Eftimov, MD, PhD, medical specialist in neurology at Amsterdam UMC
Updated Review Highlights Efficacy of Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

February 20th 2024

A recent review of studies indicated that intravenous immunoglobulin could be as effective as other treatments in improving disability for patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Pharmacokinetic Profiles of Intravenous and Subcutaneous Immunoglobulin Produce Differential Immunomodulatory Effects on Serum Cytokines in CIDP
Pharmacokinetic Profiles of Intravenous and Subcutaneous Immunoglobulin Produce Differential Immunomodulatory Effects on Serum Cytokines in CIDP

February 20th 2024

Mamatha Pasnoor, MD
FDA Approves Takeda’s Immune Globulin Infusion, Gammagard Liquid, for Chronic Inflammatory Demyelinating Polyneuropathy

January 29th 2024

Survey Highlights Treatment Needs, Perspectives of Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Survey Highlights Treatment Needs, Perspectives of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

January 25th 2024

Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit
FDA Approves Takeda’s Immune Globulin Infusion, Hyqvia, for Chronic Inflammatory Demyelinating Polyneuropathy

January 16th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.